Story Poster
Notre Dame Football Recruiting

2020 Four-Star OL Andrew Gentry Recaps Notre Dame Official Visit

April 7, 2019
6,037

2020 Columbine (Colo.) offensive lineman Andrew Gentry‍ took his first official visit this weekend and once again left Notre Dame impressed.

The 6-foot-8, 305-pounder visited in December, but this trip was different and he got to see the program in-depth

“One of the things I got out of the visit was being able to really see what it’s like to be a Notre Dame football player,” Gentry told Irish Sports Daily. “It was definitely a great insight into what life would be like if I were to go there.” 

The four-star prospect spent time with offensive line coach Jeff Quinn and Notre Dame football coach Brian Kelly, who had similar messages.

“Their message was to have me really get to know Notre Dame,” stated Gentry. “I definitely really like both of those coaches a lot.” 

48 hours on campus also provided Gentry a chance to mix it up with Notre Dame’s current offensive line. Gentry was able to get to know them and see how close the entire group is to each other. 

“It was cool to hang out with the offensive line,” said Gentry. “They definitely have some really sharp offensive linemen.” 

Gentry wasn’t the only top prospect on campus as Notre Dame hosted eight official visitors along with several signees and commits. 

It provided a chance for Gentry to get know the other prospects and get a feel of who he could be playing with in the future. 

“I feel I was able to mesh with some of the recruits,” explained Gentry. “I was able to hang out with Jimmy Christ‍ a lot and he’s a super cool guy.” 

As Gentry heads back to Colorado, he’ll start planning out the rest of his visit schedule and the Irish sit in a good position. 

“I’m still trying to finalize a couple of official visits,” said Gentry. I’ll try and commit this summer. 

“I would say Notre Dame is still towards the top of my list for sure.” 

 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.